A method for determining an intracranial hemodynamic parameter according to embodiments of the present disclosure is provided, which includes determining a three-dimensional a model of a blood vessel based on CT angiographic data, and determining at least one of a boundary condition of each inlet or a boundary condition of each outlet in the three-dimensional vessel model based on CT perfusion imaging data and CT angiographic data.

Disclosed are an optimization method and system for a personalized contrast test based on deep learning, in which a contrast medium optimized for each individual patient is injected to implement optimum pharmacokinetic characteristics in a process of acquiring a medical image, the method including: obtaining drug information of a contrast medium and body information of a patient, in a contrast enhanced computed tomography (CT) scan; generating injection information of the drug to be injected into the patient by a predefined algorithm based on the drug information and the body information; injecting the drug into the patient based on the injection information, and acquiring a medical image by scanning the patient; and amplifying a contrast component in the medical image by inputting the medical image to a deep learning model trained in advance.

Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.

An apparatus for determining a functional index for stenosis assessment of a vessel is provided. The apparatus comprises an input interface (40) and a processing unit (50). The input interface is configured to obtain image data (30) representing a two-dimensional representation of a vessel (6). The processing unit (50) is configured to determine a course of the vessel (6) and a width (w1, w2) of the vessel along its course in the image data and is further configured to determine the functional index for stenosis assessment of the vessel based on the width of the vessel in the image data.

A method for quantitative flow analysis of a fluid flowing in a conduit from a sequence of consecutive image frames of such a conduit, where such image frames are timely separated by a certain time interval, the method comprising: a) selecting a start image frame and an end image frame from the sequence either automatically or upon user input; b) determining a centerline of the conduit in the start image frame; c) determining a centerline of the conduit in the end image frame; d) selecting a common start point on the centerline of the start image frame and on the centerline of the end image frame either automatically or upon user input; e) selecting an end point on the centerline of the start image frame; f) selecting an end point on the centerline of the end image frame; g) calculating centerline distance between the start point and the end point of the start image frame; h) calculating centerline distance between the start point and the end point of the end image frame; and i) calculating a local flow velocity as a function of the centerline distances of g) and h) and a time interval between the start image frame and the end image frame.
A corresponding imaging device and computer program are also disclosed.

Methods and systems are provided for adaptive scan control. In one embodiment, a method includes upon a first contrast injection, processing acquired projection data of a subject to measure a contrast signal of the first contrast injection, estimating a time when a venous return to baseline (VRTB) of the first contrast injection is to occur based on the contrast signal, and commanding initiation of a second contrast injection at the estimated time.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and/or dynamically identify one or more features, such as plaque and vessels, and/or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, and/or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and/or quantified parameters.

A marker-coordinate detecting unit detects coordinates of a stent marker on a new image when the new image is stored in an image-data storage unit; and then a correction-image creating unit creates a correction image from the new image through, for example, image transformation processing, so as to match up the detected coordinates with reference coordinates that are coordinates of the stent marker already detected by the marker-coordinate detecting unit in a first frame. An image post-processing unit then creates an image for display by performing post-processing on the correction image created by the correction-image creating unit, the post-processing including high-frequency noise reduction filtering-processing, low-frequency component removal filtering-processing, and logarithmic-image creating processing; and then a system control unit performs control of displaying a moving image of an enlarged image of a set region that is set in the image for display, together with an original image.

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.

During a medical intervention such as an angiography, the X-ray examination equipment (such as that mounted on a C-arm) produces a very large number of imaging frames of the intervention, as it progresses. This information contains frame sequences which can be effectively used to improve a medical report of the intervention. The sequence will contain sequences which contain similar clinical information though, and these frames may be considered to be redundant and not useful for inclusion in the medical report. The aspects detailed herein enable a selection of non-redundant sequences and/or frames, based on contextual information, obtained from the sequence of images, and/or other medical equipment, during an intervention. In this way, the redundancy inherent in the original frame sequence can be removed, leaving a set of prepared candidate sequences for insertion into a multimedia or documentary medical report.